P
PMV Pharmaceuticals, Inc. (PMVP)
NMS – Real vaqt narxi. Valyuta: USD
1.42
+0.03 (2.16%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
1.42
+0.03 (2.16%)
Yopilishda: May 12, 2026, 4:00 PM EDT
PMV Pharmaceuticals, Inc., aniq onkologiya kompaniyasi, Qo'shma Shtatlarda p53 mutatsiyalari va boshqa p53 bilan bog'liq saratonlarni maqsad qilib olgan kichik molekulali terapiyalarni kashf qilish va ishlab chiqish bilan shug'ullanadi. Kompaniya rezatapoptni ishlab chiqadi, bu esa tuxumlardan qat'iy nazar kasalliklar uchun 2-bosqichli klinik sinovlarda bo'lgan p53 Y220C mutatsiyalarining selektiv tuzilmaviy korrektori hisoblanadi. Kompaniya ilgari PJ Pharmaceuticals, Inc. nomi bilan tanilgan va 2013-yil iyul oyida PMV Pharmaceuticals, Inc. deb o'zgartirilgan. PMV Pharmaceuticals, Inc. 2013-yilda tashkil etilgan va shtab-kvartirasi Nyu-Jersi shtatining Prinston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board |
| Dr. Binh Vu Ph.D. | Senior Vice President of Drug Discovery & CMC |
| Dr. David H. Mack Ph.D. | Co-Founder, CEO, President & Director |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Dr. Marc Fellous M.D. | Senior VP and Head of Clinical Development & Medical Affairs |
| Mr. Michael Carulli |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 10-Q | pmvp-20260331.htm |
| 2026-04-22 | DEFA14A | ny20064070x2_defa14a.htm |
| 2026-04-22 | DEF 14A | ny20064070x1_def14a.htm |
| 2026-03-06 | 8-K | pmvp-20260306.htm |
| 2025-11-12 | 8-K | pmvp-20251112.htm |
| 2025-09-10 | 8-K | d90438d8k.htm |
| 2025-08-07 | 8-K | pmvp-20250807.htm |
| 2025-06-09 | 8-K | d57209d8k.htm |
| 2025-05-09 | 10-Q | pmvp-20250331.htm |
| 2025-04-25 | DEFA14A | ny20041194x2_defa14a.htm |
| Chief Financial Officer |
| Mr. Robert Ticktin J.D. | General Counsel, COO & Company Secretary |
| Mr. Tim Smith M.B.A. | Senior VP and Head of Corporate Development & Investor Relations |
| Ms. Crystal Zuckerman | Vice President of Human Resources |
| Ms. Laura De Leon | VP & Head of Clinical Development Operations |